Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05928234

A Comparison of Morbidity Between Patients With Pulmonary Atresia With Intact Ventricular Septum and Uni- or Biventricular Circulation

The goal of this observational study is to compare patients with pulmonary atresia with intact ventricular septum (PA-IVS) with univentricular circulation to patients with the same heart defect but that has a biventricular circulation in regards to mortality, quality of life, comorbidity, cardiac function, and work capacity. The main questions the study aims to answer are:

• Do mortality, quality of life, comorbidity, cardiac function, and work capacity differ between patients with PA-IVS who have univentricular and biventricular circulation?

Participants will be asked to answer a Quality of Life questionnaire. The investigators will also inquire with a sample size of the research subjects (based on place of residence) about their participation in a series of examinations (ergo-spirometry to assess work capacity, transthoracic echocardiogram, magnetic resonance of the heart and blood sampling to assess cardiac function and cardiac health).

Recruiting

Interested in participating?

Request Info

Key information

Age range

15 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pediatric Heart Center, Queen Silvia's Children's hospital

Gothenburg, 416 85, Sweden

Location status: Recruiting

Location contact

stina manhem, MD

CONTACT

[email protected]

+46735080342

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals born with pulmonary atresia with intact ventricular septum (PA-IVS) who are 15 years or older at the start of the study.
  • Regarding the mortality variable, research subjects who have died after the age of 15 years old will be included.

Exclusion criteria

Individuals born with pulmonary atresia with intact ventricular septum who are younger than 15 years old at the start of the study.

Treatment and study plan

Primary outcomes

  1. Difference in comorbidity between the two groups

    Time frame: September 2024

    Difference in myocardial infarction, heart failure, arrhythmia, stroke, malignancy, autoimmune diseases, infections, atopy, certain liver diseases, and protein-losing enteropathy between the two groups

Secondary outcomes

  1. Difference in quality of life between the two groups

    Time frame: September 2024

    A validated quality of life questionnaire (PROMIS Scale v1.2-Global Health) will be sent to all the research subjects and the answers will be compared between the two groups. The questionnaire consists of a ten-item patient reported measure of physical, mental and social health. Each statement is answered on a scale from 1-5, higher scores mean better outcome.

  2. Difference in physical capacity between the two groups

    Time frame: September 2024

    Ergospirometry, outcome variables: exercise test (exercise capacity measured in watt and over time, counted in minutes), oxygen saturation (measured in percent), blood pressure (measured in millimetre of mercury)

  3. Difference in cardiac capacity between the two groups

    Time frame: September 2024

    Transthoracic echocardiogram

  4. Difference in general health, linked to cardiac health, between the two groups

    Time frame: September 2024

    The following blood tests will be analysed: N-terminal pro-brain natriuretic peptide (a marker for heart failure), Alanine aminotransferase (a liver enzyme), Aspartate aminotransferase (a liver enzyme), Creatinine (a waste product from muscle metabolism, used to assess kidney function), Sodium (an electrolyte), Potassium (an electrolyte), Hemoglobin (a protein in red blood cells that carries oxygen), White blood cell count (Leukocyte count), Platelet count (Thrombocyte count), Albumin: A protein produced by the liver that helps maintain fluid balance in the body, TREC (T-receptor excision circles): A marker used to assess immune function, specifically the production of new T cells, Expanded lymphocyte typing (a comprehensive examination of lymphocyte subtypes)

  5. Difference in mortality between the groups

    Time frame: September 2024

Study contacts

Contact information is provided by the study sponsor or research team.

stina manhem, MD

CONTACT

[email protected]

+46735080342

Sponsors and collaborators

Lead sponsor

Vastra Gotaland Region

Other Gov

Registry information

Official study title

A Longterm Follow-up and Comparison of Morbidity and Heart Health Between Patients With Pulmonary Atresia With Intact Ventricular Septum and Uni- or Biventricular Circulation

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jul 3, 2023
Registry last updated
Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.